Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MaxCyte ( (MXCT) ) has issued an update.
MaxCyte, Inc., a company involved in the biotechnology industry, has announced a change in its major shareholders as BlackRock, Inc. has increased its stake. As of February 12, 2025, BlackRock now holds 7.66% of voting rights in MaxCyte, up from a previous 7.64%, indicating a slight increase in their influence over company decisions. This adjustment in shareholding could have implications for MaxCyte’s strategic directions and governance, potentially impacting its market positioning and operational strategy moving forward.
More about MaxCyte
YTD Price Performance: 2.47%
Average Trading Volume: 52,173
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £355.7M
See more data about MXCT stock on TipRanks’ Stock Analysis page.